central nervous system news from FierceBiotech
News
ALSO NOTED: Novartis buys bigger stake in Alnylam; FDA chastises ZymoGenetics' marketing campaign;and much more...
> Novartis has scooped up a bigger share of Alnylam stock. The pharma giant now owns 13.3 percent of the company. Read more...
Emerging Drug Developer: BrainCells
BrainCells Remember when they used to say that you'd have all the brain cells you ever could have when you reached adulthood? Turns Read more...
Q Therapeutics raises $15M
Salt Lake City-based Q Therapeutics has raised $15 million in a second round of financing. The company is developing cell-based therapies for the central nervous system. It is currently running Read more...
Valeant shares jump on epilepsy trial data
Shares of Valeant Pharma jumped yesterday after the developer announced that its experimental epilepsy treatment retigabine met its primary endpoint in reducing the number of seizures by a Read more...
ALSO NOTED: Dynogen goes public; Alpharma sells ingredients unit for $395M; Arizona launches new venture fund; and much more...
> Dynogen Pharmaceuticals is going public in a buyout deal with Apex Bioventures Acquisition Corp. Dynogen shareholders will initially receive $98 million in the deal, with Dynogen merging with a Read more...
Lilly snares MS drug rights in $497M deal
Analysts applauded Canada's BioMS after it scored a rich Read more...
ALSO NOTED: Osgood promoted at ThermoGenesis; ImClone expects CEO announcement; OVATION expands pipeline; and much more...
> ThermoGenesis has promoted COO William Osgood to the CEO's post. The transition was triggered by founder Phil Coelho's move to the new position of chief technology architect. Read more...
Press Release: Roche Continues to Strengthen Research and Development Focus
Press Release: Roche Continues to Strengthen Research and Development Focus
Read more...Press Release: Roche and Synosis Therapeutics Announce Partnership to Explore Potential of Five Compounds Targeting the CNS
Press Release: Roche and Synosis Therapeutics Announce Partnership to Explore Potential of Five Compounds Targeting the CNS
Read more...Press Release: BioAxone Therapeutic Licenses Phase II Spinal Cord Injury Drug Cethrin to Boston Life Sciences
Press Release: BioAxone Therapeutic Licenses Phase II Spinal Cord Injury Drug Cethrin to Boston Life Sciences
Read more...Get more central nervous system coverage at:
Paid Research Reports
- Pipeline Insight: Nosocomial Vaccines - Minefield or Goldmine?
- Drug Approval Trends at the FDA and EMEA: Process improvements, heightened scrutiny and industry response
- Biotech 2008 – life sciences industry report (online & print)
- Is there a market for alcoholism pharmacotherapies?
- New report provides Rheumatoid Arthritis market insight